Publications by authors named "A Mochalova"

Polymer heart valves are a promising alternative to bioprostheses, the use of which is limited by the risks of calcific deterioration of devitalized preserved animal tissues. This is especially relevant in connection with the increasingly widespread use of transcatheter valves. Advances in modern organic chemistry provide a wide range of polymers that can replace biological material in the production of valve prostheses.

View Article and Find Full Text PDF
Article Synopsis
  • The study compares the effectiveness of atezolizumab plus cabozantinib versus docetaxel in patients with advanced non-small cell lung cancer (NSCLC) who did not respond to prior immunotherapy and chemotherapy.
  • Results showed similar overall survival rates: 10.7 months for the combination treatment and 10.5 months for docetaxel, with both showing comparable median progression-free survival.
  • Adverse events were reported in both treatment groups; however, a higher percentage of serious adverse events occurred in those receiving atezolizumab plus cabozantinib compared to docetaxel.
View Article and Find Full Text PDF

Poly-ε-caprolactone ((1,7)-polyoxepan-2-one; PCL) is a biodegradable polymer widely used in various fields of bioengineering, but its behavior in long-term studies appears to depend on many conditions, such as application specificity, chemical structure, in vivo test systems, and even environmental conditions in which the construction is exploited in. In this study, we offer an observation of the remote outcomes of PCL tubular grafts for abdominal aorta replacement in an in vivo experiment on a rat model. Adult Wistar rats were implanted with PCL vascular matrices and observed for 180 days.

View Article and Find Full Text PDF

The content of the soluble forms of immune checkpoint components sPD-1, sPD-L1 in blood serum, and sB7-H3, sCD314, sULBP1, sHLA-G in blood plasma of 30 melanoma patients receiving immunotherapy with anti-PD-1 antibodies (nivolumab, pembrolisumab) was measured before and in 4 and 8 weeks after the start of immunotherapy. The control group comprised 70 practically healthy donors. Standard immunoassay kits were used.

View Article and Find Full Text PDF